VRTX vs MRNA — Key Metrics
| Metric | VRTX (VERTEX PHARMACEUTICALS INC) | MRNA (MODERNA INC) |
|---|---|---|
| Price | 536.45 | 196.79 |
| Market Cap | 136.01 Billion | 79.63 Billion |
| P/E (TTM) | 34.23 | -27.8 |
| P/B (Quarterly) | 6.436 | 15.043 |
| P/S (TTM) | 10.5 | 31.53 |
| Net Profit Margin (TTM) | 30.7 | -110.5 |
| Gross Margin (TTM) | 85.5 | 28.0 |
| ROE (TTM) | 20.1 | -37.6 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Greatly Underperform
Recommendation Summary
Stock VRTX is projected to outperform the market, stock MRNA is projected to greatly underperform the market. Upfront Recommendation: VRTX.
Financial Metrics
| VRTX | Metrics | MRNA |
|---|---|---|
| $536.45 | Price | $196.79 |
| — | Market Capitalization | — |
| 10.5 | Price to Sales | 31.53 |
| 12.28 | Price to Gross Profit | 112.62 |
| 32.0 | Price to R&D | 29.96 |
| 11.64 | Price to Current Assets | 10.84 |
VRTX vs MRNA at a glance
Vertex Pharmaceuticals INC (VRTX) and Moderna INC (MRNA) are both Biotechnology companies in the Healthcare sector. VRTX is the larger, at $136.0 billion in market value against $79.6 billion for MRNA, about 1.7 times the size.
On trailing-twelve-month figures, VRTX trades at 10.5 times trailing sales and MRNA at 31.5; net profit margins are 30.7% and -110.5%.
The Upfront Investment model currently rates VRTX Outperform and MRNA Greatly Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.